Tim Smith

These data suggest benefits to pregnant mothers with this condition following early biologic intervention, with treatment leading to rapid refractory pustular psoriasis remission.

The FDA approved epinephrine nasal spray (Neffy) for the emergency treatment of allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh at least 30 kg.

Despite these findings, additional research may be necessary to evaluate emerging therapies and prognostic factors in the management of chronic actinic dermatitis.

In this interview, Chovatiya spoke with the editorial team about the global prevalence findings on patients with seborrheic dermatitis and their implications.

In this analysis, investigators highlighted the perceptions of individuals with HS and atopic dermatitis and assessed higher rates of stigmatization.

These data point to differences between genders such as time to initiation of treatment, treatment choice, response to medication, adverse events, and adherence.

These findings were the result of an active-comparator study, highlighting the benefits of betamethasone versus tacrolimus among patients with eczema.

These data from the United Arab Emirates provide insight into the comorbidities, epidemiology, patterns of treatment, and use of healthcare resources of alopecia areata patients.

This research compared the efficacy among a cohort of individuals with obesity to the general population of adult patients with eczema.

This analysis represents the first to indicate that extending guselkumab can lead to disease activity control among those with early complete skin clearance.

This segment of the latest Lungcast featured a discussion about heat and its interplay with various types of common medications.

This interview segment featured Silverberg discussing the AHEAD atopic dermatitis recommendations and their implications for clinicians and patients.

Silverberg discusses the new AHEAD recommendations for optimizing atopic dermatitis management, highlighting goals, disease severity assessments, and guidance for escalation.

In this Month in Review, the editorial team highlights major news covered in the field of dermatology, including FDA approvals, interviews, and new findings on drugs in the pipeline.

These data also suggest that personalized nutritional advice may be necessary for different individuals, due to the clinical diversity and the impact of differences.

This review of major news in pulmonology from July highlights an FDA decision regarding treatment for vaping dependence, prenatal pollution exposure’s impact on asthma, and more.

In this Lungcast segment, Bludorn speaks on commonly-seen heat-related illnesses amid a changing climate as well as how to screen for related risks.

This designation was based on the ORCA-V1 trial’s phase 2 findings indicating that cytisinicline more than doubled patients’ odds of e-cigarette cessation versus placebo.

This interview segment involved a discussion with Gooderham regarding the implications of recent clinical trial findings for patients with scalp and body psoriasis.

In this interview, Gooderham highlights the ARRECTOR study findings which led to roflumilast foam’s supplemental new drug application to the FDA.

These data highlight gender differences related to dysmorphic concern and the prevalence of body dysmorphic disorder among those with various dermatologic disorders.

In this episode of Crisis Point, 3 experts in dermatology discuss ways in which those in the field are working to improve visibility of diverse skin types within dermatology education.

This announcement follows roflumilast’s July 9 approval for the once-daily treatment of adults and children with mild to moderate atopic dermatitis.

These data indicate the need for future analyses of possible chronic urticaria activity biomarkers, as well as other elements of patient response to omalizumab treatment.

These findings support delgocitinib’s clinical benefit as a possible medication option for individuals with moderate to severe chronic hand eczema.

Adults with severe alopecia were shown to have statistically significant efficacy across 2 phase 3 clinical studies highlighted in this announcement.

These new data were announced by Aquestive Therapeutics and if approved, Anaphylm Sublingual Film could be the first orally-delivered, non-invasive severe allergy treatment.

These data highlighted new findings on the experiences of children aged 6 to 11 with uncontrolled type 2 asthma treated with dupilumab.

These new phase 3 findings from ARCADIA 1 and 2 highlight the effects of nemolizumab in combination with either topical corticosteroids or topical calcineurin inhibitors.

This meta-analysis was conducted to compare the efficacy and safety of lebrikizumab to other systemic treatments for patients with atopic dermatitis.